How big is NeuroPace, Inc.?

As of Jun 18, NeuroPace, Inc. has a market capitalization of 353.57 million, with net sales of 84.31 million and a net profit of -24.80 million over the last four quarters. The company reported shareholder's funds of 8.01 million and total assets of 94.65 million as of Dec 24.

Market Cap: As of Jun 18, NeuroPace, Inc. has a market capitalization of 353.57 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, NeuroPace, Inc. reported net sales of 84.31 million and a net profit of -24.80 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 8.01 million and total assets of 94.65 million.

What does NeuroPace, Inc. do?

NeuroPace, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $23 million and a net loss of $7 million as of March 2025. Key financial metrics include a market cap of $353.57 million, a P/E ratio of NA, and a dividend yield of 0.00%.

Overview: <BR>NeuroPace, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 23 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 353.57 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.19 <BR>Return on Equity: -102.91% <BR>Price to Book: 14.57<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold NeuroPace, Inc.?

Is NeuroPace, Inc. overvalued or undervalued?

As of June 3, 2021, NeuroPace, Inc. is considered a risky investment due to its high valuation metrics and underperformance relative to peers, despite a 51.32% return over the past year, significantly outperforming the S&P 500's 17.14%.

As of 3 June 2021, the valuation grade for NeuroPace, Inc. moved from does not qualify to risky. The company appears to be overvalued based on its financial metrics. Key ratios include a Price to Book Value of 17.77, an EV to EBIT of -22.14, and an EV to Sales of 5.06, which suggest that the company is not generating sufficient earnings relative to its valuation.<BR><BR>In comparison to its peers, NeuroPace, Inc. has a P/E ratio of -12.59, while ZimVie, Inc. has a significantly higher P/E of -80.95, and AngioDynamics, Inc. stands at -24.69. These ratios indicate that NeuroPace is underperforming relative to its peers. Notably, the stock has outperformed the S&P 500 over the past year with a return of 51.32% compared to the S&P 500's 17.14%, but this does not negate the overall valuation concerns.

Is NeuroPace, Inc. technically bullish or bearish?

As of September 3, 2025, NeuroPace, Inc. shows a mildly bearish technical trend with mixed signals across indicators, having outperformed the S&P 500 in the short term but underperformed year-to-date.

As of 3 September 2025, the technical trend for NeuroPace, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish outlook. The moving averages are mildly bearish on a daily basis, and the Bollinger Bands are also mildly bearish on both weekly and monthly time frames. The KST presents a mixed view with a bearish weekly signal and a bullish monthly signal. Dow Theory reflects a mildly bullish weekly stance but is mildly bearish monthly. The OBV is mildly bullish weekly and mildly bearish monthly.<BR><BR>In terms of performance, NeuroPace has outperformed the S&P 500 over the past week and month, with returns of 3.1% and 22.57% respectively, compared to the S&P 500's 1.05% and 2.33%. However, it has underperformed year-to-date with a return of -7.77% against the S&P 500's 12.22%. Overall, the current technical stance is mildly bearish, with mixed signals across different indicators.